Pulmonary Hypertension

PULMONARY ARTERIAL HYPERTENSION (PAH) MARKET EMERGING TRENDS, GROWTH RATE, GLOBAL DEMAND AND BUSINESS OPPORTUNITIES – BERLIN CURES GMBH, DEKA RESEARCH & DEVELOPMENT CORP., DONG- A ST - Scientect PULMONARY ARTERIAL HYPERTENSION (PAH) MARKET EMERGING TRENDS, GROWTH RATE, GLOBAL DEMAND AND BUSINESS OPPORTUNITIES – BERLIN CURES GMBH, DEKA RESEARCH & DEVELOPMENT CORP., DONG- A ST - Scientect Posted: 20 Aug 2020 02:19 AM PDT Global Pulmonary Arterial Hypertension (PAH) Market  By Drug Type (Endothelin Receptor Antagonists (ERAs), Vasodilators, Phosphodiesterase-5 inhibitors, Soluble Guanylate Cyclase Stimulators, Calcium Channel Blockers, Prostacyclin & prostacyclin analogs, Others), Route of administration (Inhalation, Injectable, Oral administration), End-users (Hospitals, Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East, and Africa) – Industry Trends & Forecast to 2026 The m...

3 Questions About the Use of Pulmonary Artery Denervation for PAH Treatment - Consultant360 3 Questions About the Use of Pulmonary Artery Denervation for PAH Treatment - Consultant360 Posted: 10 Aug 2020 11:12 AM PDT [unable to retrieve full-text content] 3 Questions About the Use of Pulmonary Artery Denervation for PAH Treatment    Consultant360 Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application - DocWire News Posted: 04 Aug 2020 11:00 PM PDT This article was originally published here Lab Chip. 2020 Aug 4. doi: 10.1039/d0lc00605j. Online ahead of print. ABSTRACT Currently used animal and cellular models for pulmonary arterial hypertension (PAH) only partially recapitulate its pathophysiology in humans and are thus inadequate in reproducing the hallmarks of the disease, inconsistent in portraying the sex-disparity, and unyielding to combinatorial study designs. Here we...

Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application - DocWire News Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application - DocWire News Posted: 04 Aug 2020 11:00 PM PDT This article was originally published here Lab Chip. 2020 Aug 4. doi: 10.1039/d0lc00605j. Online ahead of print. ABSTRACT Currently used animal and cellular models for pulmonary arterial hypertension (PAH) only partially recapitulate its pathophysiology in humans and are thus inadequate in reproducing the hallmarks of the disease, inconsistent in portraying the sex-disparity, and unyielding to combinatorial study designs. Here we sought to deploy the ingenuity of microengineering in developing and validating a tissue chip model for human PAH. We designed and fabricated a microfluidic device to emulate the luminal, intimal, medial, adventitial, and perivascular layers of a pulmonary artery. By growin...

Fusion protein holds promise for treating pulmonary arterial hypertension - Medical Xpress Fusion protein holds promise for treating pulmonary arterial hypertension - Medical Xpress Posted: 21 Jul 2020 12:00 AM PDT Credit: CC0 Public Domain Pulmonary arterial hypertension (PAH) is an insidious disease. Symptoms may begin slowly, and even before they appear, extensive damage has caused the obstruction of small arteries leading to increased blood pressure in the lungs. By the time symptoms—most notably, shortness of breath—become severe enough for someone with PAH to seek care and obtain a definitive diagnosis, the patient's chances of survival at five years are slightly better than 50 percent on currently available treatments. Paul B. Yu, MD, Ph.D., a cardiovascular medicine specialist at Brigham and Women's Hospital, has been studying PAH for more than 15 years to better understand the fundamental process in which blood ves...

Aerovate Therapeutics Launches with $72 Million and Repurposed Cancer Drug for PAH - BioSpace Aerovate Therapeutics Launches with $72 Million and Repurposed Cancer Drug for PAH - BioSpace Posted: 07 Aug 2020 12:22 PM PDT Aerovate Therapeutics secured $72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of Novartis' cancer drug Gleevec (imatinib) in a repurposed effort to treat pulmonary arterial hypertension (PAH). Aerovate launched from the RA Capital Incubator program where AV-101, an inhaled version of imatinib, which is now available as a generic cancer treatment, was initially developed. AV-101 is a proprietary dry powder formulation of imatinib that delivers the medicine directly to the lungs in hopes of benefiting PAH patients. Pulmonary arterial hypertension is a proliferative disorder of the pulmonary vasculature characterized by remodeling, constriction and occlusion of the sm...

Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy - GlobeNewswire Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy - GlobeNewswire Posted: 06 Aug 2020 06:40 AM PDT BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. , has closed on $72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension (PAH). An oral version of imatinib showed significant efficacy in a phase 3 trial as a disease-modifying therapy for PAH, but it was poorly tolerated by PAH patients because of systemic side effects. The Series A for Aerovate, which was founded and incubated by RA Capital Management, is led by Sofinnova Investments, a new investor in the c...

Outcomes Better for PAH Patients Treated at Specialty Centers... - Pulmonary Hypertension News Outcomes Better for PAH Patients Treated at Specialty Centers... - Pulmonary Hypertension News Posted: 27 Jul 2020 08:00 AM PDT People with pulmonary arterial hypertension (PAH) who are treated at specialty care centers have better survival chances and a lower likelihood of hospitalization, a study reports. These findings support referring PAH patients to specialty care centers for treatment, where factors like more careful disease monitoring might be decisive. The study, " Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center, " was published in the journal CHEST . Current guidelines suggest that PAH care be administered at care centers specialized in treating the disease. However, published data concerning whether a specialty care center improves treatment outcomes a...

New research widens continuum of risk associated with PVR in pulmonary hypertension - Healio New research widens continuum of risk associated with PVR in pulmonary hypertension - Healio Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application - DocWire News CTEPH Severity Assessed by Dual Energy CT Parameters and Hemodynamics - Pulmonology Advisor New research widens continuum of risk associated with PVR in pulmonary hypertension - Healio Posted: 05 Aug 2020 08:30 AM PDT August 05, 2020 3 min read Source/Disclosures Disclosures: Maron reports he receives personal fees from Actelion and is co-inventor of patents related to pulmonary hypertension. Please see the study for all other authors' relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to ...